Analogues nke ọgwụ insulin degludec * (insulin degludec *)

Ntụtụ 100 U / ml

1 ml nke ihe ngwọta nwere

ike - insulin degludec * - 100 PIECES (3.66 mg),

ndị mgbe ochie: phenol, metacresol, glycerol, zinc, hydrochloric acid / sodium hydroxide (maka mmezi pH), mmiri maka injection.

* nke emepụtara site na nje biology biology Saccharomycescerevisiae

Otu katriiki nwere 3 ml nke ihe ngwọta, nke ya na 300 PIECES.

Mpempe ọnya na-enweghị ntụpọ.

Ngwongwo ogwu

Mlọ ọgwụ

Mgbe ọ gbasịrị ọgwụ subcutaneous, usoro nke insulin degludec multhexamers mejupụtara soluble insulin degludec, nke na-emepụta oghere insulin na subcutaneous adipose anụ ahụ. Multihexamers ji nke nta nke nta kewapụ, na-ewepụta ndị nwere insulin degludec, nke a na-ebute nwayọ nwayọ nke ọgwụ ahụ n'ime ọbara.

Izu oke nke Tresiba® na plasma eruola mgbe ụbọchị 2-3 gachara.

A na - ekesa ihe insulin degludec ruo awa 24 yana ọrụ ya kwa ụbọchị otu ugboro kwa ụbọchị n'etiti oge awa nke abụọ na nke abụọ (AUCGIR, 0-12h, SS / AUCGIR, τ, SS = 0.5).

Mmekorita nke insulin degludec maka serum albumin kwekọrọ na ikike nke protein plasma> 99% na plasma ọbara mmadụ.

Linearity

Site na nchịkwa subcutaneous, ngụkọta nke plasma bụ nke dakọrịtara na usoro nke enyere n'ọtụtụ ọgwụgwọ.

Ndị otu ọrịa pụrụ iche

Ndị okenye, ndị ọrịa nwere agbụrụ dị iche iche, ndị ọrịa nke ndị nwoke na nwanyị dịgasị iche, ndị ọrịa nwere akụrụma ma ọ bụ ọrụ imeju

Onweghi ihe di iche gbasara ogwu gbasara ogwu nke Tresiba Penfill® n'etiti ndi agadi na ndi oria, n'etiti ndi oria di iche-iche, n'etiti ndi nwere oria na aru oria ma obu ndi oria ya na aru ike.

Enweghịkwa ọdịiche na njikwa ọgwụ nke ọgwụ ahụ dabere na okike nke onye ọrịa.

Childrenmụaka na ndị nọ n'afọ iri na ụma

Ngwongwo ogwu nke ogwu Tresiba Penfill® na omumu n’ime umuaka (1-11 rue afo) na ndi gbara ntorobia (12-18 n’afo) nke nwere oria 1 nke oria mellitus di ka ndi n’ile ndi okenye oria nke nwere otu ogwu.

Nsonaazụ nke ntụtụ insulin degludec na ụmụaka na ndị nọ ntorobịa dị elu ma e jiri ya tụnyere nke ndị okenye okenye nwere otu ọchịchị ọgwụ ahụ nye ndị ọrịa nwere ụdị shuga 1.

Mlọ ọgwụ

Tresiba® Penfill® bụ ntụnyere nke insulin na-arụ ọrụ ogologo oge nke mkpụrụ ndụ ihe omimi nke Saccharomyces cerevisiae mepụtara.

Ticheba® Penfill® bụ analog nke insulin na-arụ ọrụ mmadụ. Mgbe ogwu ogbugba subcutaneous gasịrị, ihe ndị dị na ọgwụ ahụ (insulin degludec) na-etolite soluble multihexamers na subcutaneous depot, site na nke enwere ntinye insulin degludec na-aga n'ihu na-agbanye, na-enye profaịlụ dị larịị nke ihe na mmetụta hypoglycemic nke ọgwụ ahụ.

N'ime oge elekere 24 nke mmetụta hypoglycemic nke ọgwụ na ndị ọrịa bụ ndị na-elekọta insulin degludec insulin otu ugboro kwa ụbọchị, ọgwụ Tresiba Penfill®, nke dị iche na insulin glargine, gosipụtara olu nkesa nkesa dị n'etiti ihe dị na oge awa nke abụọ na nke abụọ. (AUCGIR, 0-12h, SS / AUCGIR, mkpokọta, SS = 0,5)

Fig. 1. Ogologo awa iri abụọ na anọ elekọtara ọnụ nke glucose na - ewepụta insulinbaseum degludec insulin nke 100 PIECES / ml 0.6 PIECES / kg (1987 ọmụmụ)

Ogologo oge nke ọgwụ Tresiba Penfill® bụ ihe karịrị awa 42 n'ime usoro ọgwụgwọ ọgwụgwọ. A na-enweta ntinye uche nke ọgwụ na plasma ọbara ụbọchị 2-3 ụbọchị nchịkwa ọgwụ ahụ.

Insulin degludec na ntụnyere ọhaha gosipụtara obere ihe (oge 4) ma e jiri ya na insulin glargin kwa ụbọchị mgbanwe profaịlụ nke hypoglycemic edinam, nke a na-ahụta site na uru nke ọnụọgụ mgbanwe (CV) maka ọmụmụ hypoglycemic mmetụta nke ọgwụ karịrị otu oge ọnụọgụ 0 site na awa 24 ( AUCGIR, τ, SS) ma n'ime oge dị n'etiti awa 2 ruo 24 (AUCGIR, 2-24h, SS) (Isiokwu 1).

Tab. 1. Mgbanwe nke profaịlụ kwa ụbọchị nke mmetụta hypoglycemic nke ọgwụ Tresiba na insulin glargine dị na steeti ịha nhata na ndị ọrịa nwere ụdị ọrịa shuga 1 nke ọrịa mellitus.

Ike mgbanwe nke profaịlụ kwa ụbọchị nke hypoglycemic edinam n'oge otu oge dosing (AUCGIR, τ, SS)

Ike mgbanwe nke profaịlụ kwa ụbọchị nke hypoglycemic edinam n'oge oge site na awa 2 ruo 24 (AUCGIR, 2-24 h, SS)

CV: ọnụọgụ nke mgbanwe intraindividualual variant na%

SS: ị drugụ ọgwụ ọjọọ na ịha nhata

AUCGIR, 2-24h: mmetụta metabolic na elekere 22 gara aga nke oge nke dosing (ya bụ, enweghi mmetụta na ya nke insulin na-etinye ọbara n'oge ọmụmụ ihe mmeghe).

E gosipụtawo mmekọrịta dị n'etiti mmụba nke ọgwụ Tresiba Penfill® na mmetụta hypoglycemic n'ozuzu ya.

Ọmụmụ ihe ahụ egosighi ọdịiche pụtara ìhè na ọgwụ ọgwụ nke ọgwụ Tresiba n'etiti ndị ọrịa agadi na ndị ọrịa na-eto eto.

Arụmọrụ arụmọrụ yana nchekwa

Emere onwa ojoo iri na otu n’abuo ogwu n’eghe-oghe n’ime ogwu iri-na-abuo na iri-n’abuo n’abuo n’onodu iri-abuo, iri asaa na asaa, bu ndi oria oria mellitus (1102 ndi nwere oria 1) na ndi 3173 nwere oria shuga. ụdị ọrịa shuga 2) na-emeso Tresiba®.

Agụrụ ọgwụ nke Tresiba® na ndị ọrịa nwere ụdị shuga 1 nke mellitus (Isiokwu 3), na ndị ọrịa nwere ụdị shuga 2 na-enwetabeghị insulin tupu (ịmalite insulin na-agwọ ọrịa, Isiokwu 4), na onye natara ọgwụ insulin (mmụba nke ọgwụ insulin, Isiokwu 5) ) na usoro ọgwụ Tresiba® a kapịrị ọnụ ma ọ bụ nke na-agbanwe agbanwe (Isiokwu 6).

Enweghi ike nke ọgwụ ntụnyere (insulin detemir na insulin glargine) karịa ọgwụ Tresiba® n'ihe metụtara mbelata ọbara hemoglobin (HbA1c) site na oge mgbakwunye ruo na njedebe nke ọmụmụ. Ihe dị iche bụ sitagliptin ọgwụ, n'oge ntụnyere nke ọgwụ Tresiba® gosipụtara ọkwa ya dị elu site na mbelata HbA1c (Isiokwu 5).

Nsonaazụ nke ịtụle meta nke nyocha nke data enwetara n’oge nnwale 7 nke ụlọ ọgwụ bidoziri n’usoro nke “Ọgwụ iji ruo ebumnuche” ya na nnabata ndị ọrịa nwere ụdị 1 na ụdị ọrịa shuga nke abụọ gosipụtara abamuru nke ọgwụgwọ na Tresiba® n’ihe metụtara ala tụnyere insulin glargine therapy. , ugboro ole mmepe dị na ndị ọrịa nwere akụrụngwa hypoglycemia nke ekwenyeghi ekwenye (Isiokwu 2). Ejiri mbelata nke ọbara hypoglycemia n'oge ọgwụgwọ Tresib pla jiri glucose plasma na-ebu ọnụ dị ala karịa nke glargine insulin.

Tebụl 2. Meta nyocha nke akụkọ merenụ hypoglycemia

Mmeghe pnnabatakpoohypoglycemianamana

Atụmatụ Ego Ratio

(insulin degludec / insulin glargine)

Ngụkọta

Abalịs

1dị shuga 1 ọrịa mellitus + ụdị 2 ọrịa shuga (data izugbe)

Nkọwapụta ọgwụ ọjọọ

Insulin degludec * (Insulin degludec *) - Ọgwụ insulin degludec * (Insulin degludec *) ® Penfill ® - insulin na-arụ ọrụ na-arụ ọrụ ogologo oge, nke sitere na teknụzụ nke ihe omimi DNA na-eji ụdị Saccharomyces cerevisiae.

Insulin degludec na-ejikọ kpọmkwem na onye na - anabata insulin ụmụ mmadụ, ma na - eme ya, na - achọpụta mmetụta ọgwụ ọgwụ ya na mmetụta nke insulin mmadụ.

Mmetụta hypoglycemic nke degludec insulin bụ n'ihi ịba ụba nke glucose site na anụ ahụ mgbe agbatịchara insulin na akwara na abụba mkpụrụ ndụ yana mbelata ọnụego glucose na-emepụta site na imeju.

Ọgwụ Tresiba Penfill® bụ ọgwụ anaal nke insulin nke mmadụ nke oge dị oke, mgbe iruu subcutaneous ọ na-etolite soluble multihexamers na subcutaneous depot, site na ya ka enwere nnabata insulin degludec na-aga n'ihu ma na-adị ogologo, na-enye ihe ngosi zuru oke ma na-akwụghachi ụgwọ nke ọgwụ. N'ime oge elekere 24 nke mmetụta hypoglycemic nke ọgwụ dị na ndị ọrịa bụ ndị na-elekọta insulin degludec insulin otu ugboro n'ụbọchị, ọgwụ Tresiba Penfill®, n'adịghị ka insulin glargine, gosipụtara olu nkesa nkesa nke ihe omume n'ime oge mbụ na nke abụọ na awa 12 ( Auc_{GiR, 0-12h, SS}Auc_{GiR, mkpokọta, SS} = 0.5).

Ogologo oge nke ọgwụ Tresiba Penfill® bụ ihe karịrị awa 42 n'ime usoro ọgwụgwọ ọgwụgwọ. A na-enweta ntinye uche nke ọgwụ na plasma ọbara ụbọchị 2-3 ụbọchị nchịkwa ọgwụ ahụ.

Insulin degludec na ịha nha anya na-egosi obere ihe (4 ugboro) ma e jiri ya tụnyere insulin glargin kwa ụbọchị mgbanwe profaịlụ nke hypoglycemic edinam, nke a na-ahụta site na uru nke ọnụọgụ mgbanwe (CV) maka nyocha nke mmetụta hypoglycemic nke ọgwụ n'oge otu oge dosing (AUC)_{GiR, t, SS}) na n'ime oge dị ka awa 2 ruo 24 (AUC)_{GiR, 2-24h, SS}), lee Isiokwu 1.

Tebụl 1. Ngbanwe nke profaịlụ kwa ụbọchị nke mmetụta hypoglycemic nke ọgwụ Tresiba na insulin glargine na ọnọdụ ịha nhata na ndị ọrịa nwere ụdị ọrịa shuga 1 nke ọrịa mellitus.

CV bụ ọnụọgụ nke mgbanwe akwara intraindividual in%,

SS bụ ịta ọgwụ nke ịha nhata,

Auc_{GiR, 2-24h, SS} - utịp metabolic na awa 22 ikpeazụ nke oge nke dosing (ya bụ, enweghi mmetụta na ya nke insulin na-abanye n'ime insulin n'oge mmeghe nke ọmụmụ mwepu).

E gosipụtawo mmekọrịta dị n'etiti mmụba nke ọgwụ Tresiba Penfill® na mmetụta hypoglycemic n'ozuzu ya.

Ọmụmụ ihe ahụ egosighi ọdịiche pụtara ìhè na ọgwụ ọgwụ nke ọgwụ Tresiba n'etiti ndị ọrịa agadi na ndị ọrịa na-eto eto.

Arụmọrụ arụmọrụ yana nchekwa

E duziri 11 mba na-emeghere emepe nyocha a na-emeghere ọrịa na -eme ka atụmatụ a na-ele anya maka izuụka 26 na 52, a na-eme ya na otu dị iche iche, nke gụnyere ngụkọta ndị ọrịa 4275 (1102 ndị nwere ụdị shuga 1 na 3173 onye ọrịa nwere ụdị ọrịa shuga mellitus 2) gwọọ Tresiba®.

Agụrụ ọgwụ nke Tresiba® na ndị ọrịa nwere ụdị ọrịa shuga 1 nke na-enwetabeghị insulin tupu, yana ụdị ọrịa shuga 2 nke natara ọgwụ insulin, na usoro a kapịrị ọnụ ma ọ bụ mgbanwe mgbanwe maka Tresiba®. Enweghị ike ị ofụ ọgwụ ntụnyere (insulin detemir na insulin glargia) karịa Tresiba® n'ihe metụtara mbelata ihe ndekọ HbA._1C site na oge itinye ya rue ngwụsị nke ọmụmụ. Ewepu ya bụ sitagliptin, nke Tresiba® gosipụtara ọkwa ya dị ukwuu site na mbenata HbA_1C.

Nsonaazụ nke ọmụmụ ihe omumu ("ọgwụgwọ maka ebumnuche") maka ịmalite ọgwụgwọ insulin na ndị ọrịa nwere ụdị ọrịa shuga 2 bụ ọrịa gosipụtara mbelata 36% na ọnọdụ nke hypoglycemia nke nwapụtara (akọwapụtara dị ka ọrịa hypoglycemia nke mere n'etiti ehihie na elekere isii nke ụtụtụ) gosikwara site na ịta ọkwa glucose plasma b0.84*0.68* Agadi ọrịa ≥ afọ 650.820.65* Ọrịa shuga 1dị 11.10.83 Oge nhazi mmezi b1.020.75* Ọrịa shuga 2dị 20.83*0.68* Oge nhazi mmezi b0.75*0.62* Naanị usoro ọgwụgwọ basal na ndị ọrịa na-anabataghị insulin0.83*0.64*

* onu ahia putara ihe
a - hypoglycemia na-akwadosipụta ike bụ hypoglycemia, nke etinyere na nha nke ịba uru glucose b - akụkụ nke hypoglycemia mgbe izu 16 nke ọgwụgwọ gasịrị.

Enweghi ọgwụ mgbochi dị iche iche na insulin na ọgwụgwọ Tresiba Penfill® ruo ogologo oge.

Ọgbọ insulin na-arụ ọrụ ogologo oge

Maka ndị ọrịa mamịrị, insulin NPH mmadụ na ogologo oge analogues dị. Tebụl dị n'okpuru na-egosi ọdịiche ndị bụ isi n'etiti ọgwụ ndị a.

Na Septemba 2015, ewepụtara insulin ọhụrụ Abasaglar nke na-arụ ọrụ ogologo oge, nke fọrọ nke nta ka ọ bụrụ na Lantus nọ n'ọhịa.

Insulin na-arụ ọrụ ogologo oge

Nchịkwa nri na ọgwụ ọ (ụ (ụ (FDA, US FDA) - agencylọ ọrụ gọọmentị na-edo onwe ya n'okpuru Ngalaba Ahụike U.S na 2016 akwadoro ka anaulin insulin na-arụ ọrụ ogologo oge, Toujeo. Ngwaahịa a dị n’ahịa ụlọ ma gosipụta ịdị irè ya na ọgwụgwọ ọrịa shuga.

NPH insulin (NPH Neutral Protamine Hagedorn)

Nke a bụ ụdị insulin sịntetik emeziri na nhazi nke insulin, mana nwere protamine (protinine protein) mee ka ọ daa nwayọ. NPH nwere urukpuru. Ya mere, tupu nchịkwa, ekwesịrị iji nlezianya mee ya ka ọ gwakọta nke ọma.

NPH bụ ụdị insulin na-arụ ọrụ dị ọnụ ala. Ọ bụ ihe nwute, ọ na-ebulite nnukwu nsogbu nke hypoglycemia na ibu dị arọ, ebe ọ bụ na o nwere ọkwa dị elu na ọrụ (ọ bụ ezie na nsonaazụ ya na-eji nwayọ nwayọ dịka nke insulin na bolus).

A na-enyekarị ndị ọrịa nwere ụdị oria 1 ụdị insulin NPH kwa ụbọchị. Ndị ọrịa nwere ụdị shuga nke 2 nwere ike ịgba ọgwụ otu ugboro n'ụbọchị. Ihe niile dabere na ọkwa glucose dị n'ọbara na ntinye nke dọkịta.

Analogs insulin Ogologo Oge

A na - ahụta insulin, ihe ndị mejupụtara ọgwụ ọgwụ ndị a gbanwere nke na ha na - akwụsịlata ịmị mkpụrụ na mmetụta nke ọgwụ, a na - ahụta ka anaulin insulin nke mmadụ.

Lantus, Abasaglar, Tujeo na Tresiba nwere otu ihe ejikọtara ọnụ - oge ọrụ ga-anọ ogologo oge na arụmọrụ dị ala karịa NPH. N'akụkụ a, oriri ha na-ebelata ihe ize ndụ nke hypoglycemia na ibu ibu. Agbanyeghị, ọnụ ahịa analogues dị elu.

A na-ewere insulin Abasaglar, Lantus, na Tresiba otu ugboro n'ụbọchị. Patientsfọdụ ndị ọrịa na-ejikwa Levemir otu ugboro n'ụbọchị. Nke a anaghị emetụta ndị ọrịa shuga 1 maka ọrụ ọgwụ na-erughị awa 24.

Tresiba bụ ihe kachasị ọhụrụ ma ugbu a ụdị insulin kachasị ọnụ dị na ahịa. Agbanyeghị, ọ nwere uru dị mkpa - ọghọm hypoglycemia, karịsịa n'abalị, bụ nke kachasị ala.

Ogologo oge ole ka insulin na-adịru

Ọrụ nke insulin na-eme ogologo oge bụ ịnọchite anya nzuzo nke insulin na-anọ na ya. Ya mere, ọkwa otu hormone a dị n’ọbara na-ahụ maka ọrụ ya niile. Nke a na - eme ka mkpụrụ ndụ ahụ anyị jiri glucose etisasịworo n’ime ọbara ruo awa iri abụọ na anọ.

Etu esi abanye insulin

A na - agunye insulins niile na-eme ogologo oge n’ahụ n’akpụkpọ anụ ebe enwere abụba. Akụkụ akụkụ nke apata ụkwụ kachasị mma maka ebumnuche ndị a. Ebe a na-enye ohere iji ọgwụ nra gafee nwayọ. Dabere na nhọpụta nke endocrinologist, ịkwesịrị ime otu ma ọ bụ abụọ kwa ụbọchị.

Oge ịgba ntụtụ

Ọ bụrụ na ebumnuche gị bụ ka ị nọgide na-agba insulin dị ala ka o kwere mee, jiri Abasaglar, Lantus, Toujeo, ma ọ bụ Tresiba analogues. Otu ọgwụ ọnụ (n'ụtụtụ ma ọ bụ n'anyasị, mana oge niile n'otu ụbọchị) nwere ike inye insulin ka ọ dị otu elekere kwa elekere.

Nwere ike ịchọ ntụtụ abụọ kwa ụbọchị iji jigide ọkwa hormone dị mma mgbe ị na-ahọrọ NPH. Ma, nke a na - enyere gị aka ịhazigharị ọnụọgụ ahụ dabere n'oge ụbọchị na ọrụ - dị elu n'ụbọchị ma ọ dị obere n'oge ịrahụ ụra.

Nsogbu nke hypoglycemia n'iji insulin basal

Achọpụtala na analogs insulin na-arụ ọrụ ogologo oge anaghị enwe oke akpata hypoglycemia (karịsịa nnukwu hypoglycemia n'abalị) tụnyere NPH. Mgbe ị na-eji ha, ebumnuche ebumnuche nke haemoglobin HbA1c ga-enwerịrị.

Enwekwara ihe akaebe na iji ọgwụ analorọ insulin na-arụ ọrụ ogologo oge ma ọ bụrụ na e jiri ya tụnyere isoflan NPH na-eme ka mbelata ahụ (yana, n'ihi ya, mbelata ọgwụ na-egbochi ọgwụ na mkpa ọgwụ niile).

Diabetesdị ọrịa shuga na-arụ ọrụ ogologo oge

Ọ bụrụ na ị na-arịa oria 1 dị ka ọrịa shuga, pancreas gị enweghị ike imepụta insulin zuru ezu. Yabụ, mgbe ị risịrị nri, ị ga - eji ọgwụ na - arụ ọrụ ogologo oge nke na - emetụta izu nzuzo nke insulin site na mkpụrụ ndụ beta. Y’oburu na igba oso gi, enwere nsogbu ibute ketoacidosis nke di oria.

Mgbe ị na-ahọrọ n'etiti Abasaglar, Lantus, Levemir na Tresiba, ịkwesịrị ịma ụfọdụ atụmatụ insulin.

• Lantus na Abasaglar nwere profaịlụ dị ntakịrị karịa Levemir, na maka ọtụtụ ndị ọrịa, ha na-arụ ọrụ awa 24.
• Enwere ike ịchọrọ Levemir ugboro abụọ kwa ụbọchị.
• N'iji Levemir, enwere ike ịgbakọ doses dịka oge nke ụbọchị, si otú a belata ihe ize ndụ nke hypoglycemia nke ehihie ma melite nchịkwa ụbọchị.
• Toujeo, ọgwụ Tresibia nwere ike belata akara ngosipụta ndị a dị elu karịa ha na Lantus.
• Shouldkwesịrị ịtụle nsonaazụ ọgwụ dị ka ncha. Mmeghachi omume ndị a anaghị adịkarị obere, mana ha nwere ike ịda.
• Ọ bụrụ na ịchọrọ ịgbanwe site na analogues insulin na-arụ ọrụ ogologo oge gaa NPH, buru n'uche na ike ị doseụ ọgwụ ahụ mgbe nri gasịrị, eleghị anya ọ ga-ebelata.

Ogologo insulin na-arụ ọrụ maka ụdị shuga II

Ọgwụ maka ọrịa shuga II na-amalitekarị site na ntinye nke ezigbo nri nri na ọgwụ ọnụ (Metformin, Siofor, Diabeton, wdg ..). Agbanyeghị, enwere ọnọdụ mgbe a manyere ndị dọkịta iji ọgwụ insulin mee ihe.

Kachakarị ndị e depụtara n'okpuru:

• Mmetụta ọgwụ ọgwụ na-ezughị ezu, enweghi ike nweta glycemia nkịtị na gemoclobin glycated.
• Contraindications maka nchịkwa ọnụ
• Nchoputa onye oria di ala n’aru ọnya iri-elu, ihe iriba-ama nke ulo ogwu
• Myocardial infarction, akwara ọbara, ọrịa shuga, nnukwu ọrịa, usoro ịwa ahụ
• Ime

Profaịlụ insulin na-arụ ọrụ ogologo oge

Usoro izizi na-abụkarị 0.2 nkeji / n'arọ ahụ. Ihe mgbakoro a bara uru nye ndi mmadu n’enweghi nsogbu insulin, ya na oru ya na akuru ya. Ọ bụ dọkịta gị ka akọwapụtara ya etu ị ga-esi mee ọgwụ insulin ahụ! (

Na mgbakwunye na oge ọrụ (nke kachasị ogologo bụ degludec, nke kachasị dị mkpirikpi bụ injin insulin-isophan) nke mkpụrụ ndụ mmadụ, ọgwụ ndị a dịkwa iche iche. N'ihe banyere insulin NPH, a na-ekesa ọnụ ọgụgụ kachasị elu nke oge ka ọ na - apụta n'agbata awa anọ na iri na anọ mgbe ọ gbasịrị ya. Ihe anausaịl nọ na-arụsi ọrụ ike nke na-arụ ọrụ ogologo oge ruru ogo 6 ruo awa asatọ mgbe ọ gbasịrị ya, mana ọ na-ebelata ka ọ na -ekwu.

Ya mere, a na-akpọ insulin glargine, basal insulin. Ọbara ya na ọbara dị ala nke ukwuu, yabụ ihe egwu ọbara hypoglycemia dị obere.

Ndepụta nke analogues

Otu onye ọbịa kọrọ akụkọ oriri kwa ụbọchị